OIG Still Wary Of Anti-Kickback Safe Harbors For Value-Based Arrangements Involving Drugs
Executive Summary
US health department’s Office of Inspector General reviews its concerns with allowing remuneration from drug firms in value-based arrangements in latest report to Congress.